Boehringer Ingelheim To Focus On Precision Psychiatry In CNS
R&D Mission: Explore Brain’s Biological Circuitry
Executive Summary
Boehringer Ingelheim will increasingly use external collaborations in its search for new treatment options for neuropsychiatric diseases, its CNS R&D head tells Scrip.
You may also be interested in...
Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'
Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in health care and how life science companies can adapt from them while leveraging core capabilities at scale.
Ex-Amgen CIO McKenzie: 'We All Have To Think Like Software Companies'
Amgen’s former chief information officer Diana McKenzie highlights the inroads made by technology firms in healthcare and how life science companies can adapt from them while leveraging core capabilities at scale.
Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.